Aldosterone, a new appreciation of its role in heart failure

Pharmacotherapy

Volumn 20, Issue 9 I, 2000, Pages 1107-1115

  Cha, A J ^a   Malecha, S E ^a   Judge, K W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

HEART FAILURE; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0033810759     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.13.1107.35023     Document Type: Review

References (68)

1. Specific arrhythmias: Diagnosis and treatment. Heart block
2. Hormones and hemodynamics in heart failure
3. Chronic regulation of arterial blood pressure by ANP: Role of endogenous vasoactive endothelial factors
4. Catecholamine-induced cardiomyopathy in multiple endocrine neoplasia. A histologic, ultrastructural, and biochemical study
5. Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: Comparative and ontogenetic aspects
6. Angiotensin II associated cardiac myocyte necrosis: Role of adrenal catecholamines
7. Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes
8. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure
9. Neuroendocrine activation in relation to left ventricular function in chronic severe congestion heart failure: A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
10. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group
11. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart
12. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advance heart failure
13. Mechanism of sodium retention in heart failure: Relation to the renin-angiotensin-aldosterone system
14. Aldosterone and antialdosterone therapy in congestive heart failure
15. Regulation of arterial pressure: Role of pressure natriuresis and diuresis
16. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension
17. Inverse relation between aldosterone and large artery compliance in chronically treated heart failure patients
18. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group
19. Angiotensin II decreases, while captopril increases myocardial noradrenaline uptake: A mechanism for ACE inhibitors reducing cardiac death
20. Catecholamine mediated constrictor effects on aldosterone on vascular smooth muscle
21. Interactions of mineralocorticoids and pressor agents in vascular smooth muscle
22. Aldosterone blunts the reflex baroreceptor response to noradrenaline in healthy man
23. Magnesium deficiency and sudden death
24. Intracellular electrolytes in cardiac failure
25. Modeling of the rat right and left ventricles in experimental hypertension
26. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat
27. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
28. Increased cardiac type I and III collagen mRNAs in aldosterone salt hypertension
29. Mineralocorticoids, hypertension and cardiac fibrosis
30. Comparative effect of angiotensin-converting enzyme inhibition an angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
31. Anti-aldosterone therapy in the treatment of heart failure: New thoughts on an old hormone
32. Aldosterone and heart failure
33. The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells
34. Central hypertensive effects of aldosterone
35. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells
36. Production of aldosterone in isolated rat blood vessels
37. Myocardial production of aldosterone and corticosterone in the rat
38. Brain mineralocorticoid receptor diversity: Functional implications
39. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
40. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension
41. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension
42. Aldosterone escape during ACE inhibitor therapy in chronic heart failure
43. Ectopic arrhythmia provoking action of aldosterone
44. The effect of a mineralocorticoid antagonist on myocardial mIBG uptake in congestive heart failure
45. Aldosterone reduces baroreceptor discharge in the dog
46. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog
47. Abnormal baroreflex mechanism in congestive heart failure: Recent insights
48. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy
49. Vasodilation to acetylcholine in primary and secondary forms of human hypertension
50. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
51. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors
52. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans
53. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
54. Progression of left ventricular dysfunction during enalapril therapy, relationship with neuro-hormonal reactivation
55. Captopril in heart failure: A double-blind controlled trial
56. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
57. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
58. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
59. Captopril and spironolactone therapy in patients with refractory congestive heart failure
60. Combined spironolactone and converting enzyme inhibitor therapy for refractory heart failure
61. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])
62. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
63. Effects of an angiotensin-converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients
64. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
65. Effect of losartan compared with captopril on mortality of patients with symptomatic heart failure Randomised trial - The Losartan Heart Failure Survival Study ELITE II